SCHEMBL3671866

SCHEMBL3671866

Fc1ccc(-c2ncn(Cc3ccccc3)c2-c2ccc3[nH]ncc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.66
PRKD2 Q9BZL6 4/20 0.63
CSNK1D P48730 3/20 0.63
MAP4K4 O95819 2/20 0.63
MAPK9 P45984 2/20 0.63
SLK Q9H2G2 2/20 0.63
ERBB2 P04626 1/20 0.63
GSK3B P49841 7/20 0.54
PRKACA P17612 5/20 0.54
CDK2 P24941 5/20 0.54
CDC7 O00311 4/20 0.54
PIM1 P11309 4/20 0.54
CLK4 Q9HAZ1 3/20 0.54
MKNK2 Q9HBH9 3/20 0.54
HIPK2 Q9H2X6 1/20 0.54
TGFBR1 P36897 1/20 0.52
ROCK2 O75116 7/20 0.51
CDK5 Q00535 5/20 0.50
DYRK1A Q13627 5/20 0.50
AURKB Q96GD4 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294191 0.83 EGFR (0.90) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL30023075 0.82 MAPK14 (0.57) CSNK1DMAP4K4MAPK9AURKBCDC42BPA
Hydrochloric Acid SCHEMBL30023189 0.81 MAPK14 (0.56) CSNK1DMAP4K4MAPK9AURKBCDC42BPA
Bromide SCHEMBL30023275 0.81 MAPK14 (0.56) CSNK1DMAP4K4MAPK9AURKBCDC42BPA
SCHEMBL3670894 0.80 EGFR (1.00) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL4292705 0.79 EGFR (1.00) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL3667999 0.78 EGFR (0.88) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL18041924 0.78 EGFR (0.69) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL3669992 0.77 EGFR (1.00) EGFRPRKD2CSNK1DMAP4K4MAPK9
SCHEMBL4292679 0.77 EGFR (0.84) EGFRPRKD2CSNK1DMAP4K4MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 EGFR 876/4885PRKD2 135/4885CSNK1D 143/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 EGFR 876/4885PRKD2 135/4885CSNK1D 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.